ANNX - Mid-Cap Firm Annexon's Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study | Benzinga
On Tuesday, Annexon Inc (NASDAQ:ANNX) released topline results from its Phase 3 trial in patients with Guillain-Barré syndrome (GBS), an autoimmune condition in which the immune system attacks the nerves.
As Guillain-Barre syndrome progresses, muscle weakness can turn into paralysis.
The Phase 3 trial met its primary endpoint, with ANX005 30 mg/kg achieving a statistically significant 2.4-fold improvement on the GBS-disability scale at week 8.
ANX005 30 mg/kg treatment also demonstrated improvements versus placebo on key secondary endpoints, including early gains in muscle strength and a median of fewer days on artificial ventilation.
In a prespecified ...